SEARCH

SEARCH BY CITATION

References

  • 1
    Brammer TL, Murray EL, Fukuda K, Hall HE, Klimov A, Cox NJ. Surveillance for influenza – United States, 1997–98, 1998–99, and 1999–00 seasons. MMWR Surveill Summ 2002; 51:110.
  • 2
    Rothberg MB, Haessler SD, Brown RB. Complications of viral influenza. Am J Med 2008; 121:258264.
  • 3
    Dushoff J, Plotkin JB, Viboud C, Earn DJ, Simonsen L. Mortality due to influenza in the United States – an annualized regression approach using multiple-cause mortality data. Am J Epidemiol 2006; 163:181187.
  • 4
    Brammer L, Epperson S, Blanton L et al. Update: influenza activity – United States, August 30, 2009–March 27, 2010, and composition of the 2010–11 influenza vaccine. MMWR Morb Mortal Wkly Rep 2010; 59:423430.
  • 5
    Jain S, Kamimoto L, Bramley AM et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April–June 2009. N Engl J Med 2009; 361:19351944.
  • 6
    Libster R, Bugna J, Coviello S et al. Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1) in Argentina. N Engl J Med 2010; 362:4555.
  • 7
    Cox NJ, Subbarao K. Influenza. Lancet 1999; 354:12771282.
  • 8
    Hancock K, Veguilla V, Lu X et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009; 361:19451952.
  • 9
    Renegar KB, Small PA Jr. Passive transfer of local immunity to influenza virus infection by IgA antibody. J Immunol 1991; 146:19721978.
  • 10
    Waldman RH, Mann JJ, Kasel JA. Influenza virus neutralizing antibody in human respiratory secretions. J Immunol 1968; 100:8085.
  • 11
    Clements ML, Betts RF, Tierney EL, Murphy BR. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 1986; 24:157160.
  • 12
    Mazanec MB, Coudret CL, Fletcher DR. Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies. J Virol 1995; 69:13391343.
  • 13
    Wright PF, Murphy BR, Kervina M, Lawrence EM, Phelan MA, Karzon DT. Secretory immunological response after intranasal inactivated influenza A virus vaccinations: evidence for immunoglobulin A memory. Infect Immun 1983; 40:10921095.
  • 14
    Brokstad KA, Cox RJ, Eriksson JC, Olofsson J, Jonsson R, Davidsson A. High prevalence of influenza specific antibody secreting cells in nasal mucosa. Scand J Immunol 2001; 54:243247.
  • 15
    Ogra PL. Respiratory syncytial virus: the virus, the disease and the immune response. Paediatr Respir Rev 2004; 5:S119S126.
  • 16
    Reed JL, Welliver TP, Sims GP et al. Innate immune signals modulate antiviral and polyreactive antibody responses during severe respiratory syncytial virus infection. J Infect Dis 2009; 199:11281138.
  • 17
    Welliver TP, Garofalo RP, Hosakote Y et al. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis 2007; 195:11261136.
  • 18
    Van RK. Cytokines in the pathogenesis of influenza. Vet Microbiol 2000; 74:109116.
  • 19
    Bermejo-Martin JF, Ortiz de Lejarazu R, Pumarola T et al. Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza. Crit Care 2009; 13:R201.
  • 20
    Kawashima H, Go S, Kashiwagi Y et al. Cytokine profiles of suction pulmonary secretions from children infected with pandemic influenza A(H1N1) 2009. Crit Care 2010; 14:411.
  • 21
    Tamura S, Iwasaki T, Thompson AH et al. Antibody-forming cells in the nasal-associated lymphoid tissue during primary influenza virus infection. J Gen Virol 1998; 79:291299.
  • 22
    Coro ES, Chang WL, Baumgarth N. Type I IFN receptor signals directly stimulate local B cells early following influenza virus infection. J Immunol 2006; 176:43434351.
  • 23
    Chang WL, Coro ES, Rau FC, Xiao Y, Erle DJ, Baumgarth N. Influenza virus infection causes global respiratory tract B cell response modulation via innate immune signals. J Immunol 2007; 178:14571467.
  • 24
    Wang W, Butler EN, Veguilla V et al. Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies. J Virol Methods 2008; 153:111119.
  • 25
    Wang W, Castelan-Vega JA, Jimenez-Alberto A, Vassell R, Ye Z, Weiss CD. A mutation in the receptor binding site enhances infectivity of 2009 H1N1 influenza hemagglutinin pseudotypes without changing antigenicity. Virology 2010; 407:374380.
  • 26
    Borg I, Rohde G, Loseke S et al. Evaluation of a quantitative real-time PCR for the detection of respiratory syncytial virus in pulmonary diseases. Eur Resp J 2003; 21:944951.
  • 27
    Graham BS, Johnson TR, Peebles RS. Immune-mediated disease pathogenesis in respiratory syncytial virus infection. Immunopharmacology 2000; 48:237247.
  • 28
    Pichichero ME, Hall CB, Insel RA. A mucosal antibody response following systemic Haemophilus influenzae type B infection in children. J Clin Invest 1981; 67:14821489.
  • 29
    Faden H, Duffy L, Williams A, Krystofik DA, Wolf J. Epidemiology of nasopharyngeal colonization with nontypeable Haemophilus influenzae in the first 2 years of life. J Infect Dis 1995; 172:132135.
  • 30
    Virolainen A, Jero J, Kayhty H, Karma P, Eskola J, Leinonen M. Nasopharyngeal antibodies to pneumococcal pneumolysin in children with acute otitis media. Clin Diagn Lab Immunol 1995; 2:704707.
  • 31
    Belshe RB, Edwards KM, Vesikari T et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007; 356:685696.
  • 32
    Belshe RB, Toback SL, Yi T, Ambrose CS. Efficacy of live attenuated influenza vaccine in children 6 months to 17 years of age. Influenza Other Respi Viruses 2010; 4:141145.
  • 33
    Boyce TG, Gruber WC, Coleman-Dockery SD et al. Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children. Vaccine 1999; 18:8288.
  • 34
    Bergen R, Black S, Shinefield H et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr Infect Dis J 2004; 23:138144.